339 related articles for article (PubMed ID: 30867828)
21. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and Binding of a Novel PSMA-specific Conjugate.
Holmberg AR; Marquez M; Lennartsson L; Meurling L; Nilsson S
Anticancer Res; 2018 Mar; 38(3):1531-1537. PubMed ID: 29491082
[TBL] [Abstract][Full Text] [Related]
23. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
Ma Q; Safar M; Holmes E; Wang Y; Boynton AL; Junghans RP
Prostate; 2004 Sep; 61(1):12-25. PubMed ID: 15287090
[TBL] [Abstract][Full Text] [Related]
24. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C
Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329
[TBL] [Abstract][Full Text] [Related]
25. The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer.
Sugimoto Y; Hirota M; Yoshikawa K; Sumitomo M; Nakamura K; Ueda R; Niwa R; Suzawa T; Yamasaki M; Shitara K; Kato T; Nakamura K
Anticancer Res; 2014 Jan; 34(1):89-97. PubMed ID: 24403448
[TBL] [Abstract][Full Text] [Related]
26. A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancer.
Han D; Wu J; Han Y; Wei M; Han S; Lin R; Sun Z; Yang F; Jiao D; Xie P; Zhang L; Yang AG; Zhao A; Wen W; Qin W
Oncotarget; 2016 Sep; 7(37):59471-59481. PubMed ID: 27448970
[TBL] [Abstract][Full Text] [Related]
27. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
[TBL] [Abstract][Full Text] [Related]
28. Linc00963 Promote Cell Proliferation and Tumor Growth in Castration-Resistant Prostate Cancer by Modulating miR-655/TRIM24 Axis.
Bai M; He C; Shi S; Wang M; Ma J; Yang P; Dong Y; Mou X; Han S
Front Oncol; 2021; 11():636965. PubMed ID: 33643926
[TBL] [Abstract][Full Text] [Related]
29. A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer.
Zhou M; Wang X; Xia J; Cheng Y; Xiao L; Bei Y; Tang J; Huang Y; Xiang Q; Huang S
Int J Nanomedicine; 2020; 15():3087-3098. PubMed ID: 32431503
[TBL] [Abstract][Full Text] [Related]
30. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
Lütje S; Rijpkema M; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
J Nucl Med; 2014 Jun; 55(6):995-1001. PubMed ID: 24700882
[TBL] [Abstract][Full Text] [Related]
31. Rooibos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling.
Huang SH; Tseng JC; Lin CY; Kuo YY; Wang BJ; Kao YH; Muller CJF; Joubert E; Chuu CP
Phytomedicine; 2019 Nov; 64():153068. PubMed ID: 31419729
[TBL] [Abstract][Full Text] [Related]
32. Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization.
Novakova Z; Belousova N; Foss CA; Havlinova B; Gresova M; Das G; Lisok A; Prada A; Barinkova M; Hubalek M; Pomper MG; Barinka C
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32932591
[TBL] [Abstract][Full Text] [Related]
33. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.
Ni X; Zhang Y; Ribas J; Chowdhury WH; Castanares M; Zhang Z; Laiho M; DeWeese TL; Lupold SE
J Clin Invest; 2011 Jun; 121(6):2383-90. PubMed ID: 21555850
[TBL] [Abstract][Full Text] [Related]
34. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
Cho S; Zammarchi F; Williams DG; Havenith CEG; Monks NR; Tyrer P; D'Hooge F; Fleming R; Vashisht K; Dimasi N; Bertelli F; Corbett S; Adams L; Reinert HW; Dissanayake S; Britten CE; King W; Dacosta K; Tammali R; Schifferli K; Strout P; Korade M; Masson Hinrichs MJ; Chivers S; Corey E; Liu H; Kim S; Bander NH; Howard PW; Hartley JA; Coats S; Tice DA; Herbst R; van Berkel PH
Mol Cancer Ther; 2018 Oct; 17(10):2176-2186. PubMed ID: 30065100
[TBL] [Abstract][Full Text] [Related]
35. PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study.
Weber M; Kurek C; Barbato F; Eiber M; Maurer T; Nader M; Hadaschik B; Grünwald V; Herrmann K; Wetter A; Fendler WP
J Nucl Med; 2021 Jan; 62(1):88-91. PubMed ID: 32444377
[TBL] [Abstract][Full Text] [Related]
36. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer.
Wang F; Wu L; Yin L; Shi H; Gu Y; Xing N
Clin Transl Med; 2022 Jun; 12(6):e901. PubMed ID: 35696531
[TBL] [Abstract][Full Text] [Related]
37. Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts.
Lütje S; van Rij CM; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
Contrast Media Mol Imaging; 2015; 10(1):28-36. PubMed ID: 24764162
[TBL] [Abstract][Full Text] [Related]
38. A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy.
Xing Y; Xu K; Li S; Cao L; Nan Y; Li Q; Li W; Hong Z
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071152
[TBL] [Abstract][Full Text] [Related]
39. GR silencing impedes the progression of castration-resistant prostate cancer through the JAG1/NOTCH2 pathway via up-regulation of microRNA-143-3p.
Zhang L; Jiang H; Zhang Y; Wang C; Xia X; Sun Y
Cancer Biomark; 2020; 28(4):483-497. PubMed ID: 32568179
[TBL] [Abstract][Full Text] [Related]
40. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]